This article is more than 6 months old
05/04/2021
|
Alba Tobella

The Chinese biopharmaceutical Group Anhui Zhifei Longcom Biologic Pharmacy has developed ZF2001, a vaccine composed of protein subunits, a molecule from the binding region with the host cell. This technique includes pieces of the viral Spike protein of the SARS-CoV-2 virus, instead of including the full pathogen. The organism recognizes this alien protein, producing T lymphocytes and antibodies that will provide a memory effect able to fight the virus causing covid-19 in case we get infected in the future.

Phase III of the clinical trial of ZF2001 started in December 2020 and has the support of 29,000 volunteers from China, Ecuador, Indonesia, Pakistan, and Uzbekistan. 

The vaccine has been approved by China and Uzbekistan, but it has yet to be determined if it will be administered in two or three doses. Likewise, no data about its efficacy have been published.

Results from phases I and II discarded serious adverse reactions.

The manufacturer has not provided details about the temperature needed to preserve this vaccine.

Vaccines
Whatsapp icono

Envia'ns per WhatsApp el que vulguis verificar i ens hi posarem
695 225 233

Educació en l'era de la desinformació
Projectes d'alfabetització mediàtica i informacional per promoure una ciutadania crítica
Desfake
Icone
Et necessitem

Amb la teva aportació contribuiràs a un debat polític més saludable i ajudaràs a impulsar projectes educatius per ensenyar a navegar el caos informatiu i a defensar-se de la desinformació.

Articles relacionats

  • Bacteria do not wait five seconds to jump onto your food after it falls on the floor

  • There is no proof that cracking your knuckles harms your joints

  • At-home genetics tests are accurate for determining ancestral origins, but not for predicting diseases

Especials

Nothing Found